Health, Fitness & Food

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. U.S. stocks were mostly higher on Friday. The S & P 500 was on track for a fifth positive week in a row. The broad market index topped 5,000

Good afternoon! All eyes are on Novo Nordisk and Eli Lilly again as Wall Street looks for signs that they can address one of the biggest hurdles they faced last year. Neither company has enough supply to meet the insatiable demand for their weight loss and diabetes drugs.  One month into 2024, the two drugmakers still haven’t fully resolved those supply issues.

In this article JNJ BMY MRK Follow your favorite stocksCREATE FREE ACCOUNT Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question

Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of MRI machines and other medical equipment on Tuesday delivered

In this article CVS Follow your favorite stocksCREATE FREE ACCOUNT A CVS location in New York, US, on Thursday, Feb. 9, 2023. Stephanie Keith | Bloomberg | Getty Images CVS Health on Wednesday reported fourth-quarter revenue and adjusted earnings that topped expectations, but the company cut its full-year profit outlook, citing higher medical costs that

Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management’s upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82. Total

In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for

In this article NOVO.B-DK CTLT Follow your favorite stocksCREATE FREE ACCOUNT Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023.  Victoria Klesty | Reuters Novo Nordisk‘s parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023.  George Frey | Reuters Norway’s giant wealth fund, the world’s largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020.  Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion, in

In this article MRK Follow your favorite stocksCREATE FREE ACCOUNT The logo for Merck & Co. is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021.  Andrew Kelly | Reuters Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as

In this article BMY Follow your favorite stocksCREATE FREE ACCOUNT Dado Ruvic | Reuters Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth.  Here’s what the company reported for the fourth quarter compared with what Wall Street was expecting, based on

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024.  Brendan McDermid | Reuters Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have

January was great for the stock market. Benchmark gauges notched all-time highs, as stocks charged through a busy earnings season. The S & P 500 set records for five consecutive sessions late in the month. The Dow and Nasdaq 100 , weighted more heavily on Big Tech, closed at milestone levels, too. The Nasdaq ,

A sign for Publicis Groupe SA is seen at their headquarters in Paris, France, on Sunday, July 28, 2013.  Balint Porneczi | Bloomberg | Getty Images The health-care division of French ad giant Publicis agreed to pay $350 million to settle claims that its past marketing efforts for drugmakers helped fuel America’s opioid crisis, U.S.

Philip O’Keefe, one of Synchron’s patients in the SWITCH clinical trial, was the first person in the world to tweet using a BCI device. Source: Synchron Neurotech startup Synchron is ramping up production of its flagship brain-computer interface to prepare for commercial demand, as the company inches closer to bringing its device to market.  Synchron

We’re selling 95 shares of GE Healthcare at roughly $74. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 1,150 shares of GEHC, reducing its weighting to 2.75% from 2.97%. The small trim we’re making in GE Healthcare with the stock up slightly in an otherwise rough tape does not change our belief in this

In this article BIIB Follow your favorite stocksCREATE FREE ACCOUNT The Biogen headquarters in Cambridge, Massachusetts, on Tuesday, Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat

In this article VRTX Follow your favorite stocksCREATE FREE ACCOUNT A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Brian Snyder | Reuters Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in